News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Actavis Reports Underlying Profits Of EUR 29 Million In 3Q
November 9, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
REYKJAVIK, Iceland, Nov. 9, 2006 (PRIMEZONE) -- Actavis Group ("ACT"), the international generic pharmaceuticals company, announces its results for the third quarter ended 30 September, 2006.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Europe
MORE ON THIS TOPIC
Manufacturing
Roche pours $750M into Oregon manufacturing plant as obesity push expands
August 20, 2026
·
1 min read
·
Gabrielle Masson
IPO
Scribe’s early-stage IPO standout defies biotech’s derisking trend
August 20, 2026
·
3 min read
·
Gabrielle Masson
Rare diseases
Regeneron wins FDA approval to challenge Ipsen for rare bone disease market
August 20, 2026
·
2 min read
·
Nick Paul Taylor
Gene therapy
Ultragenyx bags first gene therapy approval as previously rejected Sanfilippo asset awaits decision
August 20, 2026
·
2 min read
·
Nick Paul Taylor
